LIDAK PHARMACEUTICALS APPOINTS J. DAVID HANSEN
9/14/98 9:20
Vice President for Sales and Marketing
SAN DIEGO, Sept. 14 /PRNewswire/ -- LIDAK Pharmaceuticals (Nasdaq: LDAKA)
today named J. David Hansen vice president for sales and marketing. Hansen's
appointment comes as the company prepares for the potential launch of its
first product, n-docosonal 10% cream, a topical treatment for oral facial
herpes infections. A new drug application (NDA) was filed with the Food and
Drug Administration in December 1997. The company anticipates an FDA decision
in the fourth quarter 1998.
"We are pleased to have David Hansen join LIDAK," said president and CEO
Gerald J. Yakatan, PhD. "As the senior director for strategic sales systems,
he was part of the management team that built Dura Pharmaceuticals into a
successful pharmaceutical company. His hands-on experience and specialized
pharmaceutical marketing and sales background will be invaluable as we
implement LIDAK's commercialization strategy."
During his ten years at Dura Pharmaceuticals, Hansen played a central role
in the development of the company's sales and marketing operations. As
national sales director, he participated in the planning, and executed three
expansions that quadrupled the size of the sales organization to four hundred
sales representatives, and directed the planning and launch of three new
products in two years.
Before joining Dura, he Was the marketing manager for Immunetech
Pharmaceuticals. He spent the fourteen years prior in various sales and
marketing positions with Schering/Key Pharmaceuticals and Bristol Myers
Squibb.
Hansen graduated with honors from University of Oregon in 1974 with a BS
in Chemistry.
LIDAK Pharmaceuticals develops therapeutic products for the treatment of
virally-caused diseases, allergy and asthma. The company filed a new drug
application (NDA) for its first product n-docosanol 10% cream, a topical
treatment for oral facial herpes, with the FDA in December 1997. A decision
by the FDA is anticipated in the fourth quarter 1998. LIDAK is currently
finalizing its product launch plans including possible co-promotional
agreements to assist with the marketing of the drug should it receive FDA
approval. The company is also seeking in-licensing agreements with other
pharmaceutical companies for late stage products to complete its drug
pipeline.
SOURCE LIDAK Pharmaceuticals
-0- 09/14/98
/NOTE TO EDITORS: The information contained in this press release,
including any forward looking statements contained herein, should be reviewed
in conjunction with the Company's Annual Report on Form 10-K and other
publicly available information regarding the Company, copies of which are
available from the Company upon request. Such publicly available information
sets forth many risks and uncertainties related to the Company's business and
such statements, including risks and uncertainties related to drug
development, clinical trials and litigation. Final decisions made by the FDA,
other regulatory agencies and the courts are unpredictable and outside of the
influence and/or control of the Company./
/CONTACT: Ann Shanahan-Walsh, Media Relations Director of LIDAK
Pharmaceuticals, 619-558-0364 ext. 212; Bob Stone or Ken DiPaola, both of The
Dilenschneider Group, 212-922-0900, for LIDAK Pharmaceuticals/
/Company News On-Call: prnewswire.com or fax, 800-758-5804,
ext. 509050/
(LDAKA)
CO: LIDAK Pharmaceuticals
ST: California
IN: MTC HEA |
